INTERVIEW: Oraya doesn't see threat from new AMD drugs
This article was originally published in Clinica
Executive Summary
Oraya Therapeutics is ramping up commercialization of its radiotherapy for age-related macular degeneration (AMD), a treatment that could disrupt a market currently dominated by drug giants Novartis and Roche with their anti-VEGF drug Lucentis. Even with the advent of new AMD drugs, such as Regeneron’s approved anti-VEGF therapy Eylea (aflibercept injection) and Ophthotech’s investigational platelet-derived growth factor (PGDF) inhibitor Fovista, Oraya remains unperturbed by its pharma rivals.